Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

C. Arthur, J. Cermak, J. Delaunay, J. Mayer, G. Mazur, X. Thomas, A. Wierzbowska, MM. Jones, E. Berrak, H. Kantarjian,

. 2015 ; 6 (-) : 25-9.

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc15014679

BACKGROUND: In a Phase III trial, 485 patients (≥65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m(2) intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m(2) subcutaneously for 10 days every 4 weeks). MATERIALS AND METHODS: We summarized overall and progression-free survival by baseline white blood cell count using two analyses: <1, 1-5, >5×10(9)/L; ≤10 or >10×10(9)/L. RESULTS: There were 446 deaths (treatment choice, n=227; decitabine, n=219). Median overall survival was 5.0 (treatment choice) versus 7.7 months (decitabine; nominal P=0.037). Overall survival differences between white blood cell groups were not significant; hazard ratios (HRs) favored decitabine. Significant progression-free survival differences favored decitabine for groups 1-5×10(9)/L (P=0.005, HR =0.67), greater than 5×10(9)/L (P=0.027, HR =0.71), and up to 10×10(9)/L (P=0.003, HR =0.72). CONCLUSION: There was a trend toward improved outcome with decitabine, regardless of baseline white blood cell count.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014679
003      
CZ-PrNML
005      
20240516120906.0
007      
ta
008      
150420s2015 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/JBM.S64067 $2 doi
035    __
$a (PubMed)25678833
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Arthur, Christopher $u Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia. $7 gn_A_00009020
245    10
$a Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia / $c C. Arthur, J. Cermak, J. Delaunay, J. Mayer, G. Mazur, X. Thomas, A. Wierzbowska, MM. Jones, E. Berrak, H. Kantarjian,
520    9_
$a BACKGROUND: In a Phase III trial, 485 patients (≥65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m(2) intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m(2) subcutaneously for 10 days every 4 weeks). MATERIALS AND METHODS: We summarized overall and progression-free survival by baseline white blood cell count using two analyses: <1, 1-5, >5×10(9)/L; ≤10 or >10×10(9)/L. RESULTS: There were 446 deaths (treatment choice, n=227; decitabine, n=219). Median overall survival was 5.0 (treatment choice) versus 7.7 months (decitabine; nominal P=0.037). Overall survival differences between white blood cell groups were not significant; hazard ratios (HRs) favored decitabine. Significant progression-free survival differences favored decitabine for groups 1-5×10(9)/L (P=0.005, HR =0.67), greater than 5×10(9)/L (P=0.027, HR =0.71), and up to 10×10(9)/L (P=0.003, HR =0.72). CONCLUSION: There was a trend toward improved outcome with decitabine, regardless of baseline white blood cell count.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Delaunay, Jacques $u Department of Clinical Hematology, University of Nantes, Nantes, France.
700    1_
$a Mayer, Jiří $u Department of Internal Medicine, Masaryk University Hospital Brno, Central European Institute of Technology, Brno, Czech Republic.
700    1_
$a Mazur, Grzegorz $u Department of Hematology, Wrocław Medical University, Wrocław, Poland.
700    1_
$a Thomas, Xavier $u Department of Hematology, Edouard Herriot Hospital, Lyon, France. $7 xx0317364
700    1_
$a Wierzbowska, Agnieszka $u Copernicus Memorial Hospital, Lodz, Poland.
700    1_
$a Jones, Mark M $u Oncology Product Creation Unit, Eisai Inc., Woodcliff Lake, NJ, USA.
700    1_
$a Berrak, Erhan $u Oncology Product Creation Unit, Eisai Inc., Woodcliff Lake, NJ, USA.
700    1_
$a Kantarjian, Hagop $u Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
773    0_
$w MED00186219 $t Journal of blood medicine $x 1179-2736 $g Roč. 6 (2015), s. 25-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25678833 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20240516120900 $b ABA008
999    __
$a ind $b bmc $g 1072260 $s 897557
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c - $d 25-9 $i 1179-2736 $m Journal of blood medicine $n J Blood Med $x MED00186219
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Archiving options